Table 2 Discontinuation of adjuvant hormone therapy and breast cancer events in women diagnosed with breast cancer in Stockholm, Sweden, 2001–2008. (A) Screening non-participants vs participants, (B) screening non-participants vs participants diagnosed with screen-detected cancers, and (C) screening non-participants vs participants diagnosed with interval cancers
Discontinuation of adjuvant hormone therapy, no. (%) | Multivariable-adjusted, HRa (95% CIs) | Breast cancer events, no. (%) | Multivariable-adjusted, HRa (95% CIs) | |||
|---|---|---|---|---|---|---|
No | Yes | No | Yes | |||
(A) Non-participants vs participants | ||||||
Participants | 822 (50.5) | 805 (49.5) | 1.00 (reference) | 3449 (83.0) | 707 (17.0) | 1.00 (reference) |
Non-participants | 146 (43.1) | 193 (56.9) | 1.30 (1.11–1.53) | 719 (76.3) | 223 (23.7) | 1.22 (1.05–1.42) |
(B) Non-participants vs participants (screen-detected cancers) | ||||||
Participants (screen-detected cancers) | 615 (50.1) | 612 (49.9) | 1.00 (reference) | 2523 (85.5) | 427 (14.5) | 1.00 (reference) |
Non-participants | 146 (43.1) | 193 (56.9) | 1.31 (1.10–1.54) | 719 (76.3) | 223 (23.7) | 1.32 (1.12–1.57) |
(C) Non-participants vs participants (interval cancers) | ||||||
Participants (interval cancers) | 207 (51.8) | 193 (48.2) | 1.00 (reference) | 926 (76.8) | 280 (23.2) | 1.00 (reference) |
Non-participants | 146 (43.1) | 193 (56.9) | 1.25 (1.02–1.53) | 719 (76.3) | 223 (23.7) | 1.05 (0.88–1.25) |